Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With Von Willebrand Disease (VWD)
Latest Information Update: 13 Jun 2024
Price :
$35 *
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Von Willebrand disease
- Focus Registrational; Therapeutic Use
- Sponsors Octapharma
- 10 Jun 2024 According to an Octapharma media release, data from the study will be presented at the upcoming ISTH 2024 Congress
- 22 Jan 2024 According to an Octapharma media release, results from this study published in the leading medical journal Blood Advances.
- 22 Jan 2024 Results presented in an Octapharma media release.